Involvement of Endogenous Digitalis-like Compounds in Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00310882|
Recruitment Status : Withdrawn (the PI is no longer work at Hadassah)
First Posted : April 5, 2006
Last Update Posted : April 8, 2011
The endogenous digitalis-like compounds (DLC)are steroid hormones synthesized and released from the adrenal gland.They are integrated in the feed-back system of the Hypothalami-Pituitary-Adrenal gland axis.One of their remarkable function is to induce apoptosis in malignant cells. Recently, accumulating data point to the possibility of using synthetic DLC as new anti-cancer drugs. Less is known about the endogenous metabolism of these compounds in cancer patients.
Proceeding from preliminary clinical data which demonstrated significantly reduced DLC plasma levels in breast cancer patients and from in vitro data which showed an impaired release of DLC towards stress stimuli in athymic nude mice,we put up the hypothesis that a latent adrenal insufficiency with low DLC levels facilitates the induction and progression of tumor diseases.
|Condition or disease|
|Breast Neoplasms Fibrocystic Disease of Breast Mammaplasty|
|Study Type :||Observational|
|Estimated Enrollment :||250 participants|
|Official Title:||Involvement of Endogenous Digitalis-like Compounds in Breast Cancer|
|Study Start Date :||May 2006|
|Estimated Study Completion Date :||May 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00310882
|Hadassah Hebrew University Medical Centers|
|Principal Investigator:||Heidrun Weideman||Hadassah Hebrew University Medical Centers|